Genetron Holdings Limited
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Genetron Holdings Limited is a China-based precision oncology platform company specializing in cancer molecular profiling and leveraging advanced technologies in molecular biology and data science to transform cancer treatment. It offers a comprehensive product and service portfolio that spans the full cycle of cancer care, including molecular diagnostic testing, early cancer screening products, companion diagnostics development, and continuous patient monitoring. Its core products comprise next-generation sequencing (NGS) platforms such as the GENETRON S2000 high-throughput sequencer and the Genetron One-Step Seq method, along with an 8-gene lung cancer assay and multiple other NMPA-approved molecular testing assays and equipment across NGS, digital PCR, and qPCR platforms. Genetron serves hospitals, clinical testing centers, and regional medical facilities primarily in China but with an emphasis on expanding the adoption of precision oncology medicine globally. Founded in 2015 and headquartered in Beijing, the company operates under a business model segmented into diagnosis and monitoring, early screening, and development services. In recent strategic developments, Genetron Holdings completed a going-private transaction in early 2024, becoming a wholly owned subsidiary of New Genetron Holding Limited, following shareholder approval and regulatory clearances. Additionally, the company has established a strategic partnership with Siemens Healthineers to promote precision oncology, enhancing capabilities in molecular profiling and cancer diagnostics through joint clinical research, technology development, and advanced training initiatives. These moves underscore Genetron’s continued emphasis on expanding its technological platform and market reach within the precision oncology space while reinforcing its commitment to innovation in cancer care delivery. The company remains focused on integrating advanced sequencing technologies, expanding its assay portfolio, and fostering collaborations to drive precision medicine adoption across China and internationally.
Gathid Sets New Identity and Access Governance Standard with Introduction of Patented Identity Model
Genetron Health Announces Completion of Going Private
Genetron Health Announces Completion of Going Private Transaction
Genetron Health Announces Shareholders' Approval of Merger Agreement
Genetron Health to Hold Extraordinary General Meeting of Shareholders
Genetron stock rallies on CEO-led deal to go private
Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction
Genetron Health Announces Receipt of Notification from
Genetron Health Announces Receipt of a Preliminary
Genetron Holdings Limited (GTH) CEO Sizhen Wang on Q1 2022 Results - Earnings Call Transcript
Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022
Genetron Holdings Limited's (GTH) CEO Sizhen Wang on Q4 2021 Results - Earnings Call Transcript
Arima Genomics Closes Series B Financing to Support Growing Portfolio of 3D Genomics Solutions for Biomedical Research and Translational Applications
Genetron Health to Announce Fourth Quarter and Full Year 2021 Unaudited Financial Results and Host Investor Call on March 29, 2022
Genetron Health to Participate in Upcoming Investor Conferences
Genetron Holdings Limited (GTH) CEO Sizhen Wang On Q3 2021 Results - Earnings Call Transcript
Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline
Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021
Genetron Added to FTSE Russell Global Equity Index Series
Genetron Health's Co-Founder and Chief Scientific Officer Awarded International Prize for Translational Neuroscience 2021